Authors:
Dibbens, JA
Polyak, SW
Damert, A
Risau, W
Vadas, MA
Goodall, GJ
Citation: Ja. Dibbens et al., Nucleotide sequence of the mouse VEGF 3 ' UTR and quantitative analysis ofsites of polyadenylation, BBA-GENE ST, 1518(1-2), 2001, pp. 57-62
Authors:
Stratmann, A
Acker, T
Burger, AM
Amann, K
Risau, W
Plate, KH
Citation: A. Stratmann et al., Differential inhibition of tumor angiogenesis by TIE2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants, INT J CANC, 91(3), 2001, pp. 273-282
Authors:
Clauss, M
Sunderkotter, C
Sveinbjornsson, B
Hippenstiel, S
Willuweit, A
Marino, M
Haas, E
Seljelid, R
Scheurich, P
Suttorp, N
Grell, M
Risau, W
Citation: M. Clauss et al., A permissive role for tumor necrosis factor in vascular endothelial growthfactor-induced vascular permeability, BLOOD, 97(5), 2001, pp. 1321-1329
Authors:
Klingler, C
Kniesel, U
Bamforth, SD
Wolburg, H
Engelhardt, B
Risau, W
Citation: C. Klingler et al., Disruption of epithelial tight junctions is prevented by cyclic nucleotide-dependent protein kinase inhibitors, HISTOCHEM C, 113(5), 2000, pp. 349-361
Citation: Hca. Drexler et al., Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells, FASEB J, 14(1), 2000, pp. 65-77
Authors:
Kappel, A
Schlaeger, TM
Flamme, I
Orkin, SH
Risau, W
Breier, G
Citation: A. Kappel et al., Role of SCL/Tal-1, GATA, and Ets transcription factor binding sites for the regulation of Flk-1 expression during murine vascular development, BLOOD, 96(9), 2000, pp. 3078-3085
Citation: Mr. Machein et al., Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2, HUM GENE TH, 10(7), 1999, pp. 1117-1128
Citation: G. Fachinger et al., Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the Angiopoietin receptor Tie-2, ONCOGENE, 18(43), 1999, pp. 5948-5953
Authors:
Muhlner, U
Mohle-Steinlein, U
Wizigmann-Voos, S
Christofori, G
Risau, W
Wagner, EF
Citation: U. Muhlner et al., Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1by Polyoma middle T oncogene, ONCOGENE, 18(29), 1999, pp. 4200-4210
Authors:
Adams, RH
Wilkinson, GA
Weiss, C
Diella, F
Gale, NW
Deutsch, U
Risau, W
Klein, R
Citation: Rh. Adams et al., Roles of ephrinB ligands and EphB receptors in cardiovascular development:demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis, GENE DEV, 13(3), 1999, pp. 295-306
Authors:
Sasaki, M
Wizigmann-Voos, S
Risau, W
Plate, KH
Citation: M. Sasaki et al., Retrovirus producer cells encoding antisense VEGF prolong survival of ratswith intracranial GS9L gliomas, INT J DEV N, 17(5-6), 1999, pp. 579-591
Authors:
Machein, MR
Kullmer, J
Ronicke, V
Machein, U
Krieg, M
Damert, A
Breier, G
Risau, W
Plate, KH
Citation: Mr. Machein et al., Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells, NEUROP AP N, 25(2), 1999, pp. 104-112
Authors:
Fong, TAT
Shawver, LK
Sun, L
Tang, C
App, H
Powell, TJ
Kim, YH
Schreck, R
Wang, XY
Risau, W
Ullrich, A
Hirth, KP
McMahon, G
Citation: Tat. Fong et al., SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, CANCER RES, 59(1), 1999, pp. 99-106
Authors:
Kappel, A
Ronicke, V
Damert, A
Flamme, I
Risau, W
Breier, G
Citation: A. Kappel et al., Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice, BLOOD, 93(12), 1999, pp. 4284-4292
Citation: Hh. Marti et W. Risau, Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors, P NAS US, 95(26), 1998, pp. 15809-15814